{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IV+Saline&page=2", "query": { "intervention": "IV Saline", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IV+Saline&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-26T14:41:23.433Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02428192", "title": "Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Leiomyosarcoma", "Unresectable Leiomyosarcoma", "Uterine Corpus Leiomyosarcoma" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 20, "start_date": "2015-05-19", "completion_date": "2021-01-28", "has_results": true, "last_update_posted_date": "2025-02-25", "last_synced_at": "2026-09-26T14:41:23.433Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02428192" }, { "nct_id": "NCT00538434", "title": "Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Eosinophilic Esophagitis" ], "interventions": [ { "name": "Reslizumab", "type": "BIOLOGICAL" }, { "name": "Saline", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Ception Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "5 Years to 18 Years" }, "enrollment_count": 227, "start_date": "2008-03", "completion_date": "2009-10", "has_results": true, "last_update_posted_date": "2016-09-02", "last_synced_at": "2026-09-26T14:41:23.433Z", "location_count": 34, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 30 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Hayward", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00538434" }, { "nct_id": "NCT01231191", "title": "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Relationship Between Intraoperative Intravenous Acetaminophen and Postoperative Opioid Avoidance for Ambulatory Surgical Procedures", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Postoperative Pain", "Intraoperative and Postoperative Opioid Requirements" ], "interventions": [ { "name": "Intravenous acetaminophen", "type": "DRUG" }, { "name": "Intravenous placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2012-03-08", "last_synced_at": "2026-09-26T14:41:23.433Z", "location_count": 1, "location_summary": "San Diego, California", "locations": [ { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01231191" }, { "nct_id": "NCT00591318", "title": "A Placebo-controlled Efficacy Study of IV Ceftriaxone for Refractory Psychosis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Psychosis", "Schizophrenia", "Schizoaffective Disorder" ], "interventions": [ { "name": "ceftriaxone", "type": "DRUG" }, { "name": "Normal Saline", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Research Foundation for Mental Hygiene, Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 12, "start_date": "2007-10-10", "completion_date": "2011-03-17", "has_results": true, "last_update_posted_date": "2022-12-02", "last_synced_at": "2026-09-26T14:41:23.433Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00591318" }, { "nct_id": "NCT00986479", "title": "This is a Study to Determine the Antidepressant Effects of AZD6765", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Treatment Resistant Major Depressive Disorder" ], "interventions": [ { "name": "AZD6765", "type": "DRUG" }, { "name": "Placebo to AZD6765", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 22, "start_date": "2009-12", "completion_date": "2011-12", "has_results": true, "last_update_posted_date": "2014-10-21", "last_synced_at": "2026-09-26T14:41:23.433Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00986479" }, { "nct_id": "NCT03711474", "title": "Dysphagia Following Anterior Cervical Spine Surgery; Single Dose Steroid vs Saline (DysDexVSSal)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Dysphagia" ], "interventions": [ { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Saline", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "West Virginia University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 78, "start_date": "2018-09-07", "completion_date": "2024-07-30", "has_results": true, "last_update_posted_date": "2025-02-12", "last_synced_at": "2026-09-26T14:41:23.433Z", "location_count": 1, "location_summary": "Morgantown, West Virginia", "locations": [ { "city": "Morgantown", "state": "West Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03711474" }, { "nct_id": "NCT02356159", "title": "Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Myelodysplastic Syndromes", "Hodgkin's Lymphoma", "Non-Hodgkin's Lymphoma", "Acute Leukemia", "Multiple Myeloma" ], "interventions": [ { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Conditioning chemotherapy", "type": "DRUG" }, { "name": "TMS", "type": "DRUG" }, { "name": "FLAG", "type": "DRUG" }, { "name": "EPOCH-F", "type": "DRUG" }, { "name": "Hematopoietic stem cell transplant", "type": "PROCEDURE" }, { "name": "Palifermin", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Epinephrine", "type": "DRUG" }, { "name": "IV Saline", "type": "OTHER" }, { "name": "ECG", "type": "DIAGNOSTIC_TEST" }, { "name": "ECHO", "type": "DIAGNOSTIC_TEST" }, { "name": "MUGA", "type": "DIAGNOSTIC_TEST" }, { "name": "DEXA", "type": "DIAGNOSTIC_TEST" }, { "name": "CT chest", "type": "DIAGNOSTIC_TEST" }, { "name": "PET", "type": "DIAGNOSTIC_TEST" }, { "name": "MRI", "type": "DIAGNOSTIC_TEST" }, { "name": "BM aspirate", "type": "PROCEDURE" }, { "name": "BM biopsy", "type": "PROCEDURE" }, { "name": "Lumbar puncture", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "OTHER", "DIAGNOSTIC_TEST" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2015-09-24", "completion_date": "2025-03-25", "has_results": true, "last_update_posted_date": "2025-09-30", "last_synced_at": "2026-09-26T14:41:23.433Z", "location_count": 2, "location_summary": "Bethesda, Maryland • Minneapolis, Minnesota", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02356159" }, { "nct_id": "NCT00571324", "title": "Effect of Exendin-(9-39) on Glycemic Control in Subjects With Congenital Hyperinsulinism", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Congenital Hyperinsulinism" ], "interventions": [ { "name": "Exendin-(9-39)", "type": "DRUG" }, { "name": "Vehicle", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Diva De Leon", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "7 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "7 Years to 60 Years" }, "enrollment_count": 9, "start_date": "2007-08", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2017-12-11", "last_synced_at": "2026-09-26T14:41:23.433Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00571324" }, { "nct_id": "NCT03040024", "title": "Delirium Prevention With Ketamine in Ear, Nose, and Throat (ENT) Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Otolaryngeal Cancer" ], "interventions": [ { "name": "Ketamine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Electroencephalogram (EEG)", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 71, "start_date": "2017-03-17", "completion_date": "2020-04-24", "has_results": true, "last_update_posted_date": "2021-07-08", "last_synced_at": "2026-09-26T14:41:23.433Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03040024" }, { "nct_id": "NCT03086343", "title": "A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis (RA)" ], "interventions": [ { "name": "Abatacept", "type": "DRUG" }, { "name": "Placebo for abatacept (0.9% Sodium Chloride Injection or Solution for Infusion)", "type": "DRUG" }, { "name": "Upadacitinib", "type": "DRUG" }, { "name": "Placebo for upadacitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 657, "start_date": "2017-05-09", "completion_date": "2023-06-06", "has_results": true, "last_update_posted_date": "2024-07-18", "last_synced_at": "2026-09-26T14:41:23.433Z", "location_count": 44, "location_summary": "Peoria, Arizona • Sun City, Arizona • Tucson, Arizona + 40 more", "locations": [ { "city": "Peoria", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03086343" } ] }